- Home
- MNOV vs TLSA Comparison
MNOV vs TLSA Comparison
Compare MNOV & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNOV
- TLSA
- Stock Information
- Founded
- MNOV 2000
- TLSA 2013
- Country
- MNOV United States
- TLSA United Kingdom
- Employees
- MNOV N/A
- TLSA N/A
- Industry
- MNOV Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- MNOV Health Care
- TLSA Health Care
- Exchange
- MNOV Nasdaq
- TLSA Nasdaq
- Market Cap
- MNOV 68.2M
- TLSA 175.3M
- IPO Year
- MNOV 2005
- TLSA 2000
- Fundamental
- Price
- MNOV $1.32
- TLSA $1.59
- Analyst Decision
- MNOV Strong Buy
- TLSA
- Analyst Count
- MNOV 2
- TLSA 0
- Target Price
- MNOV $7.00
- TLSA N/A
- AVG Volume (30 Days)
- MNOV 13.0K
- TLSA 261.4K
- Earning Date
- MNOV 08-07-2025
- TLSA 07-11-2025
- Dividend Yield
- MNOV N/A
- TLSA N/A
- EPS Growth
- MNOV N/A
- TLSA N/A
- EPS
- MNOV N/A
- TLSA N/A
- Revenue
- MNOV N/A
- TLSA N/A
- Revenue This Year
- MNOV N/A
- TLSA N/A
- Revenue Next Year
- MNOV N/A
- TLSA N/A
- P/E Ratio
- MNOV N/A
- TLSA N/A
- Revenue Growth
- MNOV N/A
- TLSA N/A
- 52 Week Low
- MNOV $1.12
- TLSA $0.63
- 52 Week High
- MNOV $2.55
- TLSA $1.91
- Technical
- Relative Strength Index (RSI)
- MNOV 45.64
- TLSA 53.42
- Support Level
- MNOV $1.32
- TLSA $1.54
- Resistance Level
- MNOV $1.38
- TLSA $1.81
- Average True Range (ATR)
- MNOV 0.05
- TLSA 0.12
- MACD
- MNOV 0.00
- TLSA 0.01
- Stochastic Oscillator
- MNOV 44.44
- TLSA 50.00
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.